Promising Future for Sana Biotechnology’s Diabetes Treatment: Buy Rating Affirmed

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Sana Biotechnology (SANA – Research Report) today and set a price target of $11.00.

Emily Bodnar’s rating is based on the promising results from Sana Biotechnology’s UP421 program, which is focused on treating Type 1 diabetes with hypoimmune-modified pancreatic islet cells. The recent 12-week data presented at the New York Stem Cell Foundation Conference demonstrated a sustained increase in C-peptide levels, indicating effective insulin production without the need for immunosuppression.
The data also highlighted the therapy’s favorable safety profile, with no signs of inflammation or graft rejection, which underscores the potential of Sana’s HIP-technology. These positive in-human results, along with the company’s plans to release further data and potentially file an IND for their iPSC-derived islet cell program, SC451, in 2026, contribute to the Buy rating. The combination of these factors suggests a promising future for Sana’s innovative approach to diabetes treatment.

Bodnar covers the Healthcare sector, focusing on stocks such as Femasys, AnaptysBio, and Olema Pharmaceuticals. According to TipRanks, Bodnar has an average return of -9.4% and a 24.05% success rate on recommended stocks.